-
Mashup Score: 44A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) - Full Text View - ClinicalTrials.gov - 6 day(s) ago
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, UrologyTweet
-
Mashup Score: 17Breast Cancer: New Horizons, Current Controversies - 8 day(s) ago
Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of healthcare professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients. The two-day course is taught by clinical experts in medical oncology, surgical oncology, radiation oncology, and pathology. Each year, the course faculty identify emerging practice gaps in breast oncology and address those gaps by translating the latest scientific knowledge into practical clinical app
Source: cmecatalog.hms.harvard.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Breast Cancer: New Horizons, Current Controversies - 8 day(s) ago
Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of healthcare professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients. The two-day course is taught by clinical experts in medical oncology, surgical oncology, radiation oncology, and pathology. Each year, the course faculty identify emerging practice gaps in breast oncology and address those gaps by translating the latest scientific knowledge into practical clinical app
Source: cmecatalog.hms.harvard.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) - Full Text View - ClinicalTrials.gov - 10 day(s) ago
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, UrologyTweet
-
Mashup Score: 35A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) - Full Text View - ClinicalTrials.gov - 10 day(s) ago
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, UrologyTweet
-
Mashup Score: 30Adjuvant Immunotherapy for Kidney Cancer — A New Strategy with New Challenges | NEJM - 10 day(s) ago
Surgery with curative intent constitutes the standard of care for patients with advanced renal-cell carcinoma, yet more than 50% of patients with high-risk features will have disease recurrence. Tw…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 22
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. In a double-blind, pha…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 80Home - 15 day(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 80Home - 16 day(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93Support Toni Choueiri, MD and Robert Haddad, MD - Pickleball for a Purpose Presented by EchoStor Technologies - 18 day(s) ago
I’m excited to join this incredible initiative! This organization’s mission is very important to me and I’m proud to help them make a difference. Please support me by giving to my page. Every dollar counts! Thank you.
Source: charity.pledgeit.orgCategories: General Medicine News, Hem/OncsTweet
Next steps (non-exhaustive list): -Biomarkers (soon!) -personalized trial: pembro+/-vaccine (https://t.co/bEuEbs0kMY) -Additive trial: Pembro +/- HIF2 inh (https://t.co/JKBKYqSgCu) -Neoadjuvant strategies (stay tuned!) Onwards and upwards!